Free Trial

GBS (GBS) Competitors

GBS logo
$1.25 -0.03 (-1.95%)
As of 05/21/2025

GBS vs. INO, NVNO, APYX, ICCM, CTSO, MODD, TELA, MDAI, DXR, and NMTC

Should you be buying GBS stock or one of its competitors? The main competitors of GBS include Inovio Pharmaceuticals (INO), enVVeno Medical (NVNO), Apyx Medical (APYX), IceCure Medical (ICCM), Cytosorbents (CTSO), Modular Medical (MODD), TELA Bio (TELA), Spectral AI (MDAI), Daxor (DXR), and NeuroOne Medical Technologies (NMTC). These companies are all part of the "surgical & medical instruments" industry.

GBS vs.

GBS (NYSE:GBS) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

GBS has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

In the previous week, Inovio Pharmaceuticals had 8 more articles in the media than GBS. MarketBeat recorded 10 mentions for Inovio Pharmaceuticals and 2 mentions for GBS. Inovio Pharmaceuticals' average media sentiment score of 0.18 beat GBS's score of -0.02 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GBS
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inovio Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

GBS's return on equity of -85.64% beat Inovio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
GBSN/A -85.64% -54.42%
Inovio Pharmaceuticals N/A -118.17%-83.47%

Inovio Pharmaceuticals received 721 more outperform votes than GBS when rated by MarketBeat users.

CompanyUnderperformOutperform
GBSN/AN/A
Inovio PharmaceuticalsOutperform Votes
721
70.69%
Underperform Votes
299
29.31%

2.8% of GBS shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 0.3% of GBS shares are held by company insiders. Comparatively, 2.3% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GBS has higher revenue and earnings than Inovio Pharmaceuticals. GBS is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GBS$440K43.32-$8.31M-$0.56-2.29
Inovio Pharmaceuticals$283.10K256.50-$135.12M-$3.19-0.62

Inovio Pharmaceuticals has a consensus target price of $9.75, suggesting a potential upside of 392.42%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than GBS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GBS
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Inovio Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Inovio Pharmaceuticals beats GBS on 11 of the 16 factors compared between the two stocks.

Get GBS News Delivered to You Automatically

Sign up to receive the latest news and ratings for GBS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GBS vs. The Competition

MetricGBSSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$19.06M$4.50B$5.38B$19.41B
Dividend YieldN/A43.63%5.21%3.83%
P/E Ratio-2.2929.4326.7634.23
Price / Sales43.3267.72389.7134.85
Price / CashN/A51.0838.2517.51
Price / Book2.916.236.784.69
Net Income-$8.31M$68.16M$3.23B$1.02B
7 Day Performance-0.39%-0.19%1.51%-1.74%
1 Month Performance5.79%19.19%10.03%7.46%
1 Year Performance-44.59%21.47%16.65%3.96%

GBS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GBS
GBS
N/A$1.26
-2.0%
N/A-47.8%$18.69M$440,000.00-2.247
INO
Inovio Pharmaceuticals
3.6533 of 5 stars
$1.92
-1.0%
$12.20
+535.4%
-82.0%$70.41M$217,756.00-0.48320
NVNO
enVVeno Medical
0.7554 of 5 stars
$3.83
+6.1%
N/A-29.5%$67.16MN/A-2.9719
APYX
Apyx Medical
0.7913 of 5 stars
$1.58
+43.0%
N/A-7.5%$59.72M$48.10M-1.90270Gap Down
High Trading Volume
ICCM
IceCure Medical
2.0951 of 5 stars
$1.04
+6.9%
$2.50
+141.2%
-5.5%$57.53M$3.29M-3.5760News Coverage
Positive News
Upcoming Earnings
Gap Up
CTSO
Cytosorbents
2.0349 of 5 stars
$0.87
0.0%
$4.67
+436.4%
-7.4%$54.47M$35.59M-2.42220News Coverage
Analyst Forecast
Analyst Revision
MODD
Modular Medical
0.8811 of 5 stars
$0.99
-3.3%
N/A-48.8%$40.09MN/A-1.8620News Coverage
TELA
TELA Bio
1.8515 of 5 stars
$0.98
-3.0%
$7.25
+639.8%
-77.3%$38.76M$69.30M-0.58120News Coverage
MDAI
Spectral AI
3.0457 of 5 stars
$1.42
+4.4%
$4.75
+234.5%
-21.6%$35.95M$29.58M-2.1883Analyst Upgrade
Analyst Revision
DXR
Daxor
3.7982 of 5 stars
$7.20
-0.8%
$25.00
+247.2%
-19.8%$34.83M$2.13M0.0037Gap Up
NMTC
NeuroOne Medical Technologies
1.741 of 5 stars
$0.64
+3.4%
$1.45
+125.2%
-42.2%$30.52M$5.75M-2.4820Gap Up
High Trading Volume

Related Companies and Tools


This page (NYSE:GBS) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners